PERCEVAL S Valve Clinical Study for Chinese Registration

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-26

Study Completion Date

2024-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, open, single arm, multi-center clinical study in China. The primary objective of this study is to demonstrate the safety and effectiveness of the PERCEVAL S heart valve when used to replace a diseased native or malfunctioning prosthetic aortic valve in the indicated Chinese population for tissue heart valve replacement and suitable to the PERCEVAL S valve.

The secondary objectives are to collect all relevant device and subject demographics, procedural and hospital discharge, short and long-term data, as described in the secondary endpoints section.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Data Collection on Perceval S Sutureless Prosthetic Aortic Valve in the Chinese Population

NCT06011148

Aortic Valve Disease

NOT_YET_RECRUITING

Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement

NCT02673697

Aortic Valve Disease Aortic Stenosis

TERMINATED NA

Safety and Effectiveness Study of Perceval S Valve for Extended CE Mark

NCT01368666

Aortic Valve Replacement

TERMINATED NA

Clinical Study to Evaluate the Performance of Perimount Heart Valve in Chinese Patients

NCT02400489

Mitral Valve or Aortic Valve Replacement

COMPLETED

Evaluating the Safety and Efficacy of Prosthetic Polymer Heart Valves for the Treatment of Aortic Valve Disease

NCT06518681

Aortic Valve Disease Aortic Valve Stenosis Aortic Valve Regurgitation

ENROLLING_BY_INVITATION NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Disease Aortic Valve Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aortic Valve Replacement with Perceval S sutureless heart valve

Patient undergoing Aortic Valve Replacement with Perceval S sutureless heart valve

Group Type OTHER

Aortic Valve Replacement with Perceval S sutureless heart valve

Intervention Type DEVICE

Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aortic Valve Replacement with Perceval S sutureless heart valve

Patients will be treated with the PERCEVAL S heart valve (PERCEVAL S valve) which is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject of age \> 60 years.
2. Subject with aortic valve stenosis or steno-insufficiency.
3. Subject has signed the informed consent.
4. Subject in which preoperative evaluation is indicated for the need of native or prosthetic aortic valve replacement via open heart surgery
5. Subject is located in a geographic location that will enable the subject to return to the study site for follow-up examinations (i.e. geographically stable).

Exclusion Criteria

1. Subject has preexisting valve prosthesis or annuloplasty rings in the mitral, pulmonic or tricuspid position.
2. Subject requires a double or multiple valve replacement or repair of the mitral, tricuspid, or pulmonic valve.
3. Subject requiring simultaneous cardiac procedures, apart from septal myectomy and/or coronary by-pass graft (CABG).
4. Subject has active endocarditis.
5. Subject has active myocarditis
6. Subject has aneurysmal dilation or dissection of the ascending aortic wall.
7. Subject is drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent.
8. Subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the subject.
9. Subject with known hypersensitivity to nickel alloys.
10. Subject is undergoing renal dialysis for chronic renal failure or has hyperparathyroidism.
11. Subject has had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized for ≥30 days prior to the planned valve implant surgery.
12. Subject is known to be noncompliant or is unlikely to complete the study.
13. Subject with an aortic root enlargement, where the ratio between the diameter of the STJ and the annulus diameter, assessed by TEE, is \> 1.3. Or for other anatomical reasons that not suitable for PERCEVAL S per IB.

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No